Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 10/2017

Open Access 01-10-2017 | Diabetes and Pregnancy (M-F Hivert, Section Editor)

Application of One-Step IADPSG Versus Two-Step Diagnostic Criteria for Gestational Diabetes in the Real World: Impact on Health Services, Clinical Care, and Outcomes

Authors: Florence M. Brown, Jennifer Wyckoff

Published in: Current Diabetes Reports | Issue 10/2017

Login to get access

Abstract

Purpose of Review

This paper seeks to summarize the impact of the one-step International Association of Diabetes and Pregnancy Study Groups (IADPSG) versus the two-step gestational diabetes mellitus (GDM) criteria with regard to prevalence, outcomes, healthcare delivery, and long-term maternal metabolic risk.

Recent Findings

Studies demonstrate a 1.03–3.78-fold rise in the prevalence of GDM with IADPSG criteria versus baseline criteria. Women with GDM by IADPSG criteria have more adverse pregnancy outcomes than women with normal glucose tolerance (NGT). Treatment of GDM by IADPSG criteria may be cost effective. Use of the fasting glucose as a screen before the 75-g oral glucose tolerance test to rule out GDM with fasting plasma glucose (FPG) < 4.4 (80 mg/dl) and rule in GDM with FPG ≥ 5.1 mmol/l (92 mg/dl) reduces the need for OGTT by 50% and its cost and inconvenience. The prevalence of postpartum abnormal glucose metabolism is higher for women with GDM diagnosed by IADPSG criteria versus that for women with NGT.

Summary

Data support the use of IADPSG criteria, if the cost of diagnosis and treatment can be controlled and if lifestyle can be optimized to reduce the risk of future diabetes.
Literature
1.
• Agarwal MM, Dhatt GS, Othman Y. Gestational diabetes: differences between the current international diagnostic criteria and implications of switching to IADPSG. J Diabetes Complicat. 2015;29(4):544–9. Prevalence of GDM in a high-risk population using several different global criteria for the one-step method ranged from 9.2% (CDA 2003) to 45.3% (IADPSG), a 5-fold difference. Furthermore, use of IADPSG criteria resulted in a 6-fold higher prevalence compared to a historical prevalence of 7.7%, when NDDG criteria were applied. CrossRefPubMed
2.
Sacks DB. Diagnosis of gestational diabetes mellitus: it is time for international consensus. Clin Chem. 2014;60(1):141–3.CrossRefPubMed
3.
Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991–2002.CrossRefPubMed
4.
Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676–82.CrossRefPubMed
5.
Jiwani A, Marseille E, Lohse N, Damm P, Hod M, Kahn JG. Gestational diabetes mellitus: results from a survey of country prevalence and practices. J Matern Fetal Neonatal Med. 2012;25(6):600–10.CrossRefPubMed
6.
O'Sullivan J. MC. Criteria for the oral glucose tolerance test in pregnancy. Diabetes (New York, NY). 1964;13:278–285.
7.
Conn JW, Fajans SS. The prediabetic state: a concept of dynamic resistance to a genetic diabetogenic influence. Diabetes. 1962;11:335.PubMed
8.
Wilkerson HL, Krall LP, Butler FK. Diabetes in a New England town. IV. 12-year progress report on the 70 diabetics found in the original Oxford, Mass., study. JAMA : the journal of the American Medical Association. 1962;179:652–4.CrossRefPubMed
9.
10.
McMillin J. Blood glucose. In: Walker HKHW, Hurst JW, editors. Clinical methods: the history, physical, and laboratory examinations. 3rd ed. Boston: Butterworths; 1990.
11.
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28(12):1039–57.
12.
Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol. 1982;144(7):768–73.CrossRefPubMed
13.
Harper LM, Mele L, Landon MB, Carpenter MW, Ramin SM, Reddy UM, et al. Carpenter-Coustan compared with National Diabetes Data Group Criteria for diagnosing gestational diabetes. Obstet Gynecol. 2016;127(5):893–8.CrossRefPubMedPubMedCentral
14.
Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, et al. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361(14):1339–48.CrossRefPubMedPubMedCentral
15.
Brown CJ, Dawson A, Dodds R, Gamsu H, Gillmer M, Hall M, et al. Report of the Pregnancy and Neonatal Care Group. Diabetic medicine : a journal of the British Diabetic Association. 1996;13(9 Suppl 4):S43–53.
16.
Hoffman L, Nolan C, Wilson JD, Oats JJ, Simmons D. Gestational diabetes mellitus—management guidelines. The Australasian Diabetes in Pregnancy Society. Med J Aust. 1998;169(2):93–7.PubMed
17.
Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization; 1999.
18.
Boyadzhieva MV, Atanasova I, Zacharieva S, Tankova T, Dimitrova V. Comparative analysis of current diagnostic criteria for gestational diabetes mellitus. Obstetric Medicine. 2012;5(2):71–7.CrossRefPubMedPubMedCentral
19.
Sermer M, Naylor CD, Gare DJ, Kenshole AB, Ritchie JW, Farine D, et al. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am J Obstet Gynecol. 1995;173(1):146–56.CrossRefPubMed
20.
Sacks DA, Greenspoon JS, Abu-Fadil S, Henry HM, Wolde-Tsadik G, Yao JF. Toward universal criteria for gestational diabetes: the 75-gram glucose tolerance test in pregnancy. Am J Obstet Gynecol. 1995;172(2 Pt 1):607–14.CrossRefPubMed
21.
HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: associations with neonatal anthropometrics. Diabetes. 2009;58(2):453–9.
22.
Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, Metzger BE, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Diabetes Care. 2012;35(3):526–8.CrossRefPubMedPubMedCentral
23.
Ogunyemi DA, Fong A, Rad S, Fong S, Kjos SL. Attitudes and practices of healthcare providers regarding gestational diabetes: results of a survey conducted at the 2010 meeting of the International Association of Diabetes in Pregnancy Study Group (IADPSG). Diabet Med. 2011;28(8):976–86.CrossRefPubMed
24.
ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 30, September 2001 (replaces Technical Bulletin Number 200, December 1994). Gestational diabetes. Obstet Gynecol. 2001;98(3):525–38.CrossRef
25.
Vandorsten JP, Dodson WC, Espeland MA, Grobman WA, Guise JM, Mercer BM, et al. NIH consensus development conference: diagnosing gestational diabetes mellitus. NIH consensus and state-of-the-science statements. 2013;29(1):1–31.PubMed
26.
Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Aktary WM, et al. Screening and diagnosing gestational diabetes mellitus. Evidence report/technology assessment. 2012;210:1–327.
27.
Feig DS, Hwee J, Shah BR, Booth GL, Bierman AS, Lipscombe LL. Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996–2010. Diabetes Care. 2014;37(6):1590–6.CrossRefPubMed
28.
Lavery JA, Friedman AM, Keyes KM, Wright JD, Ananth CV. Gestational diabetes in the United States: temporal changes in prevalence rates between 1979 and 2010. BJOG: An International Journal of Obstetrics & Gynaecology. 2016:n/a-n/a.
29.
Jenum AK, Morkrid K, Sletner L, Vangen S, Torper JL, Nakstad B, et al. Impact of ethnicity on gestational diabetes identified with the WHO and the modified International Association of Diabetes and Pregnancy Study Groups criteria: a population-based cohort study. Eur J Endocrinol. 2012;166(2):317–24.CrossRefPubMedPubMedCentral
30.
Olagbuji BN, Atiba AS, Olofinbiyi BA, Akintayo AA, Awoleke JO, Ade-Ojo IP, et al. Prevalence of and risk factors for gestational diabetes using 1999, 2013 WHO and IADPSG criteria upon implementation of a universal one-step screening and diagnostic strategy in a sub-Saharan African population. Eur J Obstet Gynecol Reprod Biol. 2015;189:27–32.CrossRefPubMed
31.
Ekeroma AJ, Chandran GS, McCowan L, Ansell D, Eagleton C, Kenealy T. Impact of using the International Association of Diabetes and Pregnancy Study Groups criteria in South Auckland: prevalence, interventions and outcomes. Aust N Z J Obstet Gynaecol. 2015;55(1):34–41.CrossRefPubMed
32.
Helseth R, Salvesen O, Stafne SN, Morkved S, Salvesen KA, Carlsen SM. Gestational diabetes mellitus among Nordic Caucasian women: prevalence and risk factors according to WHO and simplified IADPSG criteria. Scand J Clin Lab Invest. 2014;74(7):620–8.CrossRefPubMed
33.
•• Duran A, Saenz S, Torrejon MJ, Bordiu E, Del Valle L, Galindo M, et al. Introduction of IADPSG criteria for the screening and diagnosis of gestational diabetes mellitus results in improved pregnancy outcomes at a lower cost in a large cohort of pregnant women: the St. Carlos Gestational Diabetes Study. Diabetes Care. 2014;37:2442-50 This study concluded that €14,358.06 could be saved per 100 women using IADPSG versus CC to diagnose GDM. They estimated that the new criteria would increase treatment costs by €3753.79, but reduce laboratory costs by €1587.76, and further reduce delivery and NICU costs by €16,336.90. Most cost savings were related to a predicted reduction in CS and NICU admissions.
34.
O'Sullivan EP, Avalos G, O'Reilly M, Dennedy MC, Gaffney G, Dunne FP. Atlantic DIP: the prevalence and consequences of gestational diabetes in Ireland. Ir Med J. 2012;105(5 Suppl):13–5.PubMed
35.
Morikawa M, Yamada T, Yamada T, Akaishi R, Nishida R, Cho K, et al. Change in the number of patients after the adoption of IADPSG criteria for hyperglycemia during pregnancy in Japanese women. Diabetes Res Clin Pract. 2010;90(3):339–42.CrossRefPubMed
36.
Hirst JE, Tran TS, Do MA, Morris JM, Jeffery HE. Consequences of gestational diabetes in an urban hospital in Viet Nam: a prospective cohort study. PLoS Med. 2012;9(7):e1001272.CrossRefPubMedPubMedCentral
37.
Savona-Ventura C, Vassallo J, Marre M, Karamanos BG. Hyperglycaemia in pregnancy in Mediterranean women. Acta Diabetol. 2012;49(6):473–80.CrossRefPubMed
38.
Sevket O, Ates S, Uysal O, Molla T, Dansuk R, Kelekci S. To evaluate the prevalence and clinical outcomes using a one-step method versus a two-step method to screen gestational diabetes mellitus. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2014;27(1):36–41.CrossRef
39.
Thapa P, Shrestha S, Flora MS, Bhattarai MD, Thapa N, Mahat B, et al. Gestational diabetes mellitus—a public health concern in rural communities of Nepal. J Nepal Health Res Counc. 2015;13(31):175–81.PubMed
40.
Wei Y, Yang H, Zhu W, Yang H, Li H, Yan J, et al. International Association of Diabetes and Pregnancy Study Group criteria is suitable for gestational diabetes mellitus diagnosis: further evidence from China. Chin Med J. 2014;127(20):3553–6.PubMed
41.
Alfadhli E. Gestational diabetes in Saudi women identified by the International Association of Diabetes and Pregnancy Study Group versus the former American Diabetes Association criteria: a prospective cohort study. Annals of Saudi medicine. 2015;35(6):428–34.CrossRefPubMed
42.
Sibartie P, Quinlivan J. Implementation of the International Association of Diabetes and Pregnancy Study Groups criteria: not always a cause for concern. J Pregnancy. 2015;2015:754085.CrossRefPubMedPubMedCentral
43.
Mayo K, Melamed N, Vandenberghe H, Berger H. The impact of adoption of the international association of diabetes in pregnancy study group criteria for the screening and diagnosis of gestational diabetes. Am J Obstet Gynecol. 2015;212(2):224–e1-9.CrossRefPubMed
44.
Seshiah V, Balaji V, Shah SN, Joshi S, Das AK, Sahay BK, et al. Diagnosis of gestational diabetes mellitus in the community. J Assoc Physicians India. 2012;60:15–7.PubMed
45.
Kun A, Tornoczky J, Tabak AG. The prevalence and predictors of gestational diabetes mellitus in Hungary. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2011;43(11):788–93.CrossRefPubMed
46.
Reyes-Munoz E, Parra A, Castillo-Mora A, Ortega-Gonzalez C. Effect of the diagnostic criteria of the International Association of Diabetes and Pregnancy Study Groups on the prevalence of gestational diabetes mellitus in urban Mexican women: a cross-sectional study. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2012;18(2):146–51.CrossRef
47.
Trujillo J, Vigo A, Duncan BB, Falavigna M, Wendland EM, Campos MA, et al. Impact of the International Association of Diabetes and Pregnancy Study Groups criteria for gestational diabetes. Diabetes Res Clin Pract. 2015;108(2):288–95.CrossRefPubMed
48.
Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352(24):2477–86.CrossRefPubMed
49.
• Waters TP, Dyer AR, Scholtens DM, Dooley SL, Herer E, Lowe LP, et al. Maternal and neonatal morbidity for women who would be added to the diagnosis of GDM using IADPSG criteria: a secondary analysis of the hyperglycemia and adverse pregnancy outcome study. Diabetes Care. 2016;39(12):2204–10. Untreated women with GDM by IADPSG criteria (excluding those who also met CC criteria) had increased preeclampsia, primary CS, LGA, cord C-peptide, and newborn percentage body fat above the 90th percentile, indicating higher risk of adverse outcomes compared to women with NGT. CrossRefPubMed
50.
Ethridge JK Jr, Catalano PM, Waters TP. Perinatal outcomes associated with the diagnosis of gestational diabetes made by the international association of the diabetes and pregnancy study groups criteria. Obstet Gynecol. 2014;124(3):571–8.CrossRefPubMedPubMedCentral
51.
O'Sullivan EP, Avalos G, O'Reilly M, Dennedy MC, Gaffney G, Dunne F. Atlantic Diabetes in Pregnancy (DIP): the prevalence and outcomes of gestational diabetes mellitus using new diagnostic criteria. Diabetologia. 2011;54(7):1670–5.CrossRefPubMed
52.
Lindqvist M, Persson M, Lindkvist M, Mogren I. No consensus on gestational diabetes mellitus screening regimes in Sweden: pregnancy outcomes in relation to different screening regimes 2011 to 2012, a cross-sectional study. BMC pregnancy and childbirth. 2014;14(1):185.CrossRefPubMedPubMedCentral
53.
Bodmer-Roy S, Morin L, Cousineau J, Rey E. Pregnancy outcomes in women with and without gestational diabetes mellitus according to the International Association of the Diabetes and Pregnancy Study Groups criteria. Obstet Gynecol. 2012;120(4):746–52.CrossRefPubMed
54.
Sacks DA, Black MH, Li X, Montoro MN, Lawrence JM. Adverse pregnancy outcomes using the International Association of the Diabetes and Pregnancy Study Groups criteria: glycemic thresholds and associated risks. Obstet Gynecol. 2015;126(1):67–73.CrossRefPubMed
55.
Black MH, Sacks DA, Xiang AH, Lawrence JM. Clinical outcomes of pregnancies complicated by mild gestational diabetes mellitus differ by combinations of abnormal oral glucose tolerance test values. Diabetes Care. 2010;33(12):2524–30.CrossRefPubMedPubMedCentral
56.
March MI, Modest AM, Ralston SJ, Hacker MR, Gupta M, Brown FM. The effect of adopting the IADPSG screening guidelines on the risk profile and outcomes of the gestational diabetes population. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2016;29(7):1141–5.CrossRef
57.
Pan L, Leng J, Liu G, Zhang C, Liu H, Li M, et al. Pregnancy outcomes of Chinese women with gestational diabetes mellitus defined by the IADPSG’s but not by the 1999 WHO’s criteria. Clin Endocrinol. 2015;83(5):684–93.CrossRef
58.
Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25(10):1862–8.CrossRefPubMed
59.
Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;373(9677):1773–9.CrossRefPubMed
60.
• Noctor E, Crowe C, Carmody LA, Kirwan B, O'Dea A, Glynn LG, et al. ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by International Association of Diabetes in Pregnancy Study Groups criteria. Acta Diabetol. 2015;52(1):153–60. 75-g OGTTs at 12 weeks’ postpartum in women with GDM based on the IADPSG criteria had 5.6% prevalence of glucose abnormalities (14.1% IFG and/or IGT and 1.5% DM2) compared to that of 0.8% of women with NGT. At repeat testing (mean follow-up of GDM of 2.6 years), another 10.4% of those with a history of GDM had developed abnormal glucose levels compared to only 2.8% of those without history of GDM. CrossRefPubMed
61.
Bartakova V, Maluskova D, Muzik J, Belobradkova J, Kankova K. Possibility to predict early postpartum glucose abnormality following gestational diabetes mellitus based on the results of routine mid-gestational screening. Biochemia medica. 2015;25(3):460–8.CrossRefPubMedPubMedCentral
62.
•• Agarwal MM, Dhatt GS, Othman Y. Gestational diabetes in a tertiary care hospital: implications of applying the IADPSG criteria. Arch Gynecol Obstet. 2012;286(2):373–8. If an FPG < 4.4 (80 mg/dl) rules out GDM and > 5.1 mmol/l (92 mg/dl) rules in GDM, then no additional testing is required. This avoids the need for > 50% of the OGTTs. The authors point out that in high-risk populations GCT adds an unnecessary screen and risks missing 20% with a false negative screen as well as those who do not show for the second step OGTT (18% in this study). CrossRefPubMed
63.
Mission JF, Ohno MS, Cheng YW, Caughey AB. Gestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis. Am J Obstet Gynecol. 2012;207(4):326–e1-9.CrossRefPubMedPubMedCentral
64.
Werner EF, Pettker CM, Zuckerwise L, Reel M, Funai EF, Henderson J, et al. Screening for gestational diabetes mellitus: are the criteria proposed by the International Association of the Diabetes and Pregnancy Study Groups cost-effective? Diabetes Care. 2012;35(3):529–35.CrossRefPubMedPubMedCentral
65.
Weile LK, Kahn JG, Marseille E, Jensen DM, Damm P, Lohse N. Global cost-effectiveness of GDM screening and management: current knowledge and future needs. Best practice & research Clinical obstetrics & gynaecology. 2015;29(2):206–24.CrossRef
66.
Standards of medical care in diabetes—2011. Diabetes Care. 2011;34 Suppl 1:S11–61.
67.
Blumer I, Hadar E, Hadden DR, Jovanovic L, Mestman JH, Murad MH, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227–49.CrossRefPubMed
68.
WHO Guidelines Approved by the Guidelines Review Committee. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva: World Health Organization Copyright (c) World Health Organization 2013; 2013.
69.
Committee opinion no. 504: screening and diagnosis of gestational diabetes mellitus. Obstetrics and gynecology. 2011;118(3):751–3.
70.
Practice bulletin no. 137: gestational diabetes mellitus. Obstetrics and gynecology. 2013;122(2 Pt 1):406–16.
71.
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20(7):1183–97.
72.
Williams CB, Iqbal S, Zawacki CM, Yu D, Brown MB, Herman WH. Effect of selective screening for gestational diabetes. Diabetes Care. 1999;22(3):418–21.CrossRefPubMed
73.
Avalos GE, Owens LA, Dunne F. Applying current screening tools for gestational diabetes mellitus to a European population: is it time for change? Diabetes Care. 2013;36(10):3040–4.CrossRefPubMedPubMedCentral
74.
Hughes RCE, Moore MP, Gullam JE, Mohamed K, Rowan J. An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care. 2014;37(11):2953–9.CrossRefPubMed
75.
Zhu W-w, Yang H-x, Y-m W, Yan J, Wang Z-l, X-l L, et al. Evaluation of the value of fasting plasma glucose in the first prenatal visit to diagnose gestational diabetes mellitus in China. Diabetes Care. 2013;36(3):586–90.CrossRefPubMedPubMedCentral
76.
Alunni ML, Roeder HA, Moore TR, Ramos GA. First trimester gestational diabetes screening—change in incidence and pharmacotherapy need. Diabetes Res Clin Pract. 2015;109(1):135–40.CrossRefPubMed
77.
Yeral MI, Ozgu-Erdinc AS, Uygur D, Seckin KD, Karsli MF, Danisman AN. Prediction of gestational diabetes mellitus in the first trimester, comparison of fasting plasma glucose, two-step and one-step methods: a prospective randomized controlled trial. Endocrine. 2014;46(3):512–8.CrossRefPubMed
78.
Schousboe K, Henriksen JE, Kyvik KO, Sorensen TI, Hyltoft PP. Reproducibility of S-insulin and B-glucose responses in two identical oral glucose tolerance tests. Scand J Clin Lab Invest. 2002;62(8):623–30.CrossRefPubMed
79.
Donovan L, Hartling L, Muise M, Guthrie A, Vandermeer B, Dryden DM. Screening tests for gestational diabetes: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159(2):115–22.CrossRefPubMed
80.
Wei YM, Yang HX, Zhu WW, Yang HY, Li HX, Kapur A. Effects of intervention to mild GDM on outcomes. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2015;28(8):928–31.CrossRef
81.
Trujillo J, Vigo A, Reichelt A, Duncan BB, Schmidt MI. Fasting plasma glucose to avoid a full OGTT in the diagnosis of gestational diabetes. Diabetes Res Clin Pract. 2014;105(3):322–6.CrossRefPubMed
82.
Sevket O, Sevket A, Ozel A, Dansuk R, Kelekci S. The use of HbA1c as an aid in the diagnosis of gestational diabetes mellitus. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2014;34(8):690–2.CrossRef
83.
Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2015;131(Suppl 3):S173–211.CrossRef
84.
Catalano PM, Vargo KM, Bernstein IM, Amini SB. Incidence and risk factors associated with abnormal postpartum glucose tolerance in women with gestational diabetes. Am J Obstet Gynecol. 1991;165(4 Pt 1):914–9.CrossRefPubMed
Metadata
Title
Application of One-Step IADPSG Versus Two-Step Diagnostic Criteria for Gestational Diabetes in the Real World: Impact on Health Services, Clinical Care, and Outcomes
Authors
Florence M. Brown
Jennifer Wyckoff
Publication date
01-10-2017
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 10/2017
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-017-0922-z

Other articles of this Issue 10/2017

Current Diabetes Reports 10/2017 Go to the issue

Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors)

Animal Models of Diabetic Retinopathy

Psychosocial Aspects (S Jaser, Section Editor)

Shared Dysregulation of Homeostatic Brain-Body Pathways in Depression and Type 2 Diabetes

Pathogenesis of Type 2 Diabetes and Insulin Resistance (RM Watanabe, Section Editor)

Re-visiting the Endocannabinoid System and Its Therapeutic Potential in Obesity and Associated Diseases

Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin

Therapies and New Technologies in the Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

Management of Type 1 Diabetes in the Hospital Setting

Therapies and New Technologies in the Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

Multivariable Adaptive Artificial Pancreas System in Type 1 Diabetes
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits